A new antibody drug for Parkinson's disease appears to slow the progression of its movement-related symptoms, at least in some patients.
A first-of-its kind antibody treatment may slow the progression of movement problems in some people with Parkinson's disease (PD), early clinical trial data suggest. Current treatments for PD only ease its symptoms; they don't address its underlying causes in the brain. Now, the new antibody, called prasinezumab, has shown promise in treating one cause of the disease and thus in slowing down its movement symptoms, such as tremors and stiffness. One of the main drivers of PD is thought to be the accumulation of an abnormal version of a protein called alpha synuclein in the brain. Prasinezumab targets and helps break down these protein clumps, with the goal of slowing the disease. Read more...
No comments:
Post a Comment